N-of-One is an oncology diagnostics platform that enables clinical interpretation of molecular tests. Read more

29 Followers on Owler
29 Followers on Owler
29 Followers on Owler
29 Followers on Owler

N-of-One is an oncology diagnostics platform that enables clinical interpretation of molecular tests. Read more

Christine M. Cournoyer's photo - CEO of N-of-One

CEO

Christine M. Cournoyer

CEO Approval Rating

83/100

Founded:

2008

Status:

PrivateSubsidiary of QIAGEN GmbH

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

OpGen is the top competitor of N-of-One. OpGen is headquartered in Gaithersburg, Maryland, and was founded in 2002. OpGen competes in the Biotechnology field. OpGen generates 66% the revenue of N-of-One.

AutoGenomics is perceived as one of N-of-One's biggest rivals. AutoGenomics was founded in Carlsbad, California} in 1999. AutoGenomics operates in the Biotechnology industry. Compared to N-of-One, AutoGenomics generates $17.4M more revenue.

T2 Biosystems is seen as one of N-of-One's top competitors. T2 Biosystems is a Public company that was founded in Lexington, Massachusetts in 2006. T2 Biosystems competes in the Health Care Equipment industry. T2 Biosystems has 118 fewer employees vs. N-of-One.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Accelerate Diagnostics a competitor of N-of-One?

Acquisitions

No recent acquisitions found related to N-of-One

N-of-One Funding History

$749K$2.6M$9.6M$16.6M

Since N-of-One was founded in 2008, it has participated in 4 rounds of funding. In total N-of-One has raised $16.6M. N-of-One's last funding round was on Jan 2017 for a total of $7.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Equity
Jan 2017
$7M
-
Series B
Jul 2016
$7M
Debt
Dec 2013
$1.9M
-
Equity
Aug 2011
$749K
-

Since N-of-One was founded in 2008, it has participated in 4 rounds of funding. In total N-of-One has raised $16.6M. N-of-One's last funding round was on Jan 2017 for a total of $7.0M

Investments

No recent investments found related to N-of-One

N-of-One News

November 15, 2016HIT Consultant

Philips, N-of-One Partner to Speed Clinical Interpretation of Cancer Genomics

Royal Philips and N-of-One, Inc., a provider of clinical interpretation of molecular tests in oncolog... See more »
October 12, 2016Market Cheetah

Inova Schar Cancer Institute Partners with N-of-One to Support the Launch of Inova's Molecular Tumor Board

CONCORD, Mass.-(BUSINESS WIRE)-N-of-One, Inc., a precision medicine oncology decision support company... See more »
July 22, 2016FierceBiotech

N-of-One raises $7M to advance molecularly matched clinical trial tech

UPDATED: N-of-One raises $7M to advance molecularly matched clinical trial tech ntaylor Fri, 07/22/20... See more »

N-of-One Press Releases

November 18, 2015BUSINESS WIRE

N-of-One® Teams with the Personalized Medicine Coalition (PMC) to Support Physician Education on the Complexities of Interpreting NGS Panels in Oncology

LEXINGTON, Mass.--(BUSINESS WIRE)--N-of-One announced that N-of-One has contributed its first article... See more »
November 17, 2015BUSINESS WIRE

N-of-One Selected by WuXi NextCODE for Global Relationship, to Provide Clinical and Scientific Evidence for Interpretation for Cancer

LEXINGTON, Mass.--(BUSINESS WIRE)--N-of-One announced a global agreement with WuXi NextCODE to provid... See more »
October 6, 2015BUSINESS WIRE

N-of-One Launches PrecisionInsights for Cost Effective, Quality Clinical Interpretation of 15-20 Gene NGS Solid Tumor Panels

LEXINGTON, Mass.--(BUSINESS WIRE)--N-of-One, Inc. announced N-of-One PrecisionInsights , a new clinic... See more »
August 18, 2015BUSINESS WIRE

N-of-One Selected by Spectrum Health to Provide Clinical Interpretation for 50-Gene Hot-Spot Solid Tumor Panel

LEXINGTON, Mass.--(BUSINESS WIRE)--N-of-One has signed an agreement with Spectrum Health to provide c... See more »
August 5, 2015BUSINESS WIRE

GenomiCare Partners with N-of-One to Provide High-quality Clinical Interpretation for Comprehensive Next-generation Sequencing Tests in China

LEXINGTON, Mass. & SHANGHAI--(BUSINESS WIRE)--N-of-One, Inc. and GenomiCare Biotechnology announce a ... See more »
July 22, 2015BUSINESS WIRE

CompanionDx® Selects N-of-One's Cost-effective, High-quality Clinical Interpretation for Targeted Next-generation Sequencing Tests

LEXINGTON, Mass.--(BUSINESS WIRE)--N-of-One announced that CompanionDx has selected N-of-One to provi... See more »

Social Media

Headquarters

561 Virginia Road Suite 300

Concord, Massachusetts01742

1-617-202-9808

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

N-of-One is an oncology diagnostics platform that enables clinical interpretation of molecular tests. N-of-One was founded in 2008. N-of-One's headquarters is located in Concord, Massachusetts, USA 01742. It has raised 16.6M in 4 rounds. The latest ro...

CEO

N-of-One's CEO, Christine M. Cournoyer, currently has an approval rating of 83%. N-of-One's primary competitors are OpGen, AutoGenomics & T2 Biosystems.

Website

n-of-one.com

Frequently Asked Questions about N-of-One

  1. When was N-of-One founded?

    N-of-One was founded in 2008
  2. Who is N-of-One's CEO?

    N-of-One's CEO is Christine M. Cournoyer
  3. How much revenue does N-of-One generate?

    N-of-One generates $5.6M in revenue
  4. How much funding does N-of-One have?

    N-of-One has historically raised $16.6M in funding
  1. Where is N-of-One's headquarters?

    N-of-One's headquarters is in Concord Massachusetts, USA
  2. How many employees does N-of-One have?

    N-of-One has 269 employees
  3. What sector does N-of-One operate in?

    N-of-One is in Health Care Facilities
  4. Who are N-of-One's competitors?

    N-of-One's top competitors are OpGen, AutoGenomics, T2 Biosystems